drugset / Trial / NCT03460015

Sevoflurane in Chronic Obstructive Pulmonary Disease Exacerbation

NCT03460015

Terminated 16 enrolled University Hospital, Montpellier
RandomizedParallel-groupOpen-labelTreatment

Summary

Prospective, open-label, single-center, study to investigate the effect of sevoflurane sedation compared to a propofol-controlled arm during COPD exacerbation requiring invasive mechanical ventilation in ICU. Primary outcome measure: Evolution of airway resistance before and after sevoflurane in COPD patients, Secondary outcomes measures: Respiratory mechanics (Maximum pressure, PEEPi and PEEPtot, trapped volume), Gas exchange by the help of blood gases, The heterogeneity of alveolar ventilation by electro-impedancemetry, Evolution of pulmonary inflammation, Trophicity and contractility of the diaphragm,

Timeline

Start
2018-03-01
Primary completion
2020-09-19
Completion
2020-12-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Propofol Small molecule
Subject Sevoflurane Other / unclassified